L
Luis M. Montuenga
Researcher at University of Navarra
Publications - 245
Citations - 10844
Luis M. Montuenga is an academic researcher from University of Navarra. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 48, co-authored 221 publications receiving 9205 citations. Previous affiliations of Luis M. Montuenga include Chartered Institute of Management Accountants & Carlos III Health Institute.
Papers
More filters
Journal ArticleDOI
αCP-4, Encoded by a Putative Tumor Suppressor Gene at 3p21, But Not Its Alternative Splice Variant αCP-4a, Is Underexpressed in Lung Cancer
Ruben Pio,Isabel Zudaire,Irene Pino,Zafira Castaño,Natalia Zabalegui,Silvestre Vicent,Fermin Garcia-Amigot,María D. Odero,Maria D. Lozano,Jesús García-Foncillas,María José Calasanz,Luis M. Montuenga +11 more
TL;DR: Induction of αCP-4 expression reduced cell growth, in agreement with its proposed role as a tumor suppressor, and suggesting an association of this RNA-binding protein with lung carcinogenesis.
Journal ArticleDOI
Localization of amidating enzymes (PAM) in rat gastrointestinal tract.
Alfredo Martínez,María A. Burrell,M Kuijk,Luis M. Montuenga,Anthony M. Treston,Frank Cuttitta,J.M. Polak +6 more
TL;DR: The absence of immunoreactivity for the Amidating enzymes in endocrine cells of the small intestine, known to produce C-terminally amidated peptides, suggests the existence of other amidating enzymes.
Journal ArticleDOI
Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors.
Eva Pros,M Saigi,Daniel Alameda,Gema Gomez-Mariano,Beatriz Martinez-Delgado,Juan J. Alburquerque-Bejar,Julian Carretero,Raul Tonda,Anna Esteve-Codina,I. Català,Ramon Palmero,M. Jove,Conxi Lázaro,Ana Patiño-García,Ignacio Gil-Bazo,Ignacio Gil-Bazo,S. Verdura,A Teulé,J Torres-Lanzas,David Sidransky,Noemi Reguart,Ruben Pio,Ruben Pio,O. Juan-Vidal,Ernest Nadal,Enriqueta Felip,Luis M. Montuenga,Luis M. Montuenga,Montserrat Sanchez-Cespedes +28 more
TL;DR: The preferential occurrence of RB1 inactivation, via complex rearrangements, found in EGFR-mutant tumors appears to favor SCLC/LuSCC transformation under growth-inhibition pressures, and demonstrates that a subset of NSK-LuADs arises within cancer-predisposition syndromes.
Journal ArticleDOI
In situ detection of AE2 anion-exchanger mRNA in the human liver
TL;DR: Intense anion-exchanger-2 hybridization signals were observed in lymphomononuclear cells in sinusoids and in portal infiltrates, and Immunocytochemical data from reverse-phase sections suggest that these cells correspond to some of the CD45R+ (UCHL1+) T lymphocytes resident in the liver.
Journal ArticleDOI
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
Esther Redin,Irati Garmendia,Teresa Lozano,Diego Serrano,Yaiza Senent,Miriam Redrado,Maria Villalba,Carlos E. de Andrea,Francisco Exposito,Daniel Ajona,Sergio Ortiz-Espinosa,Ana Remirez,Cristina Bértolo,Cristina Sainz,Juana M. García-Pedrero,Ruben Pio,Juan José Lasarte,Jackeline Agorreta,Luis M. Montuenga,Alfonso Calvo +19 more
TL;DR: In this paper, the authors evaluated the impact of the SRC family kinases (SFKs) on NSCLC prognosis, and the immunomodulatory effect of the SFK inhibitor dasatinib, in combination with anti-PD-1, in clinically relevant mouse models of non-small cell lung cancer.